Eton Pharmaceuticals (ETON) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Eton Pharmaceuticals will report Q1 2026 results before the market opens on May 12, with analysts forecasting $0.10 EPS and $22.312 million in revenue and an earnings call scheduled for May 14 at 4:30 PM ET.
• In the prior quarter the company missed EPS estimates (reported $0.05 vs. $0.12 consensus) while posting $21.28 million in revenue, and analysts project roughly $1 EPS for the current fiscal year and $2 EPS next year.
• Shares recently traded around $30.84 with a 12‑month range of $13.09–$32.31; the average analyst rating is Hold with an average target of $39.33, though several brokers have raised price targets (up to $52), and institutional ownership is about 27.9%.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $22.3120 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 2.60% and a negative net margin of 5.75%.The firm had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. On average, analysts expect Eton Pharmaceuticals to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock traded up $0.68 during mid-day trading on Tuesday, reaching $30.84. 272,204 shares of the company were exchanged, compared to its average volume of 342,265. The company has a fifty day simple moving average of $21.94 and a 200-day simple moving average of $18.48. Eton Pharmaceuticals has a 12 month low of $13.09 and a 12 month high of $32.31. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.57 and a quick ratio of 1.17. The firm has a market cap of $843.81 million, a PE ratio of -171.60 and a beta of 0.82.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ETON. Zacks Research lowered Eton Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. B. Riley Financial boosted their price objective on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a "buy" rating in a research report on Friday, March 20th. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday, March 20th. Finally, HC Wainwright boosted their price objective on Eton Pharmaceuticals from $37.00 to $52.00 and gave the stock a "buy" rating in a research report on Friday, March 20th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $39.33.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ETON. Millennium Management LLC lifted its stake in shares of Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company's stock valued at $4,620,000 after purchasing an additional 217,042 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Eton Pharmaceuticals by 34.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company's stock valued at $2,274,000 after purchasing an additional 45,341 shares during the period. Jane Street Group LLC lifted its stake in shares of Eton Pharmaceuticals by 49.1% in the 1st quarter. Jane Street Group LLC now owns 95,919 shares of the company's stock valued at $1,245,000 after purchasing an additional 31,596 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Eton Pharmaceuticals by 114.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company's stock valued at $3,457,000 after purchasing an additional 129,467 shares during the period. Finally, Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at about $41,000. Institutional investors own 27.86% of the company's stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.